News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SensiGen LLC Options Epigenetic Biomarkers for Early Detection and Monitoring of Lupus


7/11/2007 10:41:39 AM

ANN ARBOR, Mich. & PHILADELPHIA--(BUSINESS WIRE)--SensiGen LLC, a biotechnology company developing advanced gene-based molecular diagnostics, announced today that it has acquired an option from the University of Michigan to exclusively license a set of epigenetic biomarkers for early detection and monitoring of Lupus. The technology includes a patented panel of proprietary biomarkers for epigenetic variations of genes uniquely associated with Lupus along with related research assays. SensiGen intends to develop commercial diagnostic assays for these novel biomarkers using the Company’s ultra-sensitive, ultra-specific AttoSense™ technology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES